KRAS and TP53 somatic mutations are two of the most common and well characterized mutations in CRC, a disease that develops in a stepwise fashion in terms of genetic mutations, activation of oncogenes and loss of function of tumor suppressing genes (Vogelstein et al., 1988; Fearon and Vogelstein, 1990; Smith et al., 2002; Hasbullah and Musa, 2021). This evidence concerns the gene KRAS and colorectal carcinoma.